My Final project
Self-Destructing Antimicrobial Biofilms
1. Full project documentation
Overview
The following documentation presents the complete scientific rationale, engineering logic, and biological architecture for a novel self-destructing antimicrobial biofilm system. The project addresses the dual challenge of antimicrobial surface protection and biological containment through engineered Bacillus subtilis 168 biofilms capable of producing two distinct antimicrobial agents, followed by programmed self-lysis via a phage-derived kill switch. The system is designed as a three-module genetic circuit: (1) a sensor-priming module that detects microbial contamination and activates the antimicrobial arsenal; (2) an effector module producing the lantibiotic subtilin and the antimicrobial peptide cecropin with broad-spectrum activity against Gram-positive and Gram-negative pathogens; and (3) a kill switch module utilizing PBSX prophage holin-endolysin genes xhlA and xhlB under a time-delayed or chemically inducible promoter. Also, a market justification is presented demonstrating a USD 10.98 billion antimicrobial coating market, the genetic circuit architecture explaining why sequential coincidence detection logic supersedes classical Boolean AND gates, the molecular biology of biofilm formation and chassis selection, detailed antimicrobial mechanisms, kill switch technology, and comprehensive molecular methods including PCR, Golden Gate assembly, and chromosomal integration. The work is structured around three strategic aims that progressively build from justification through design to implementation, culminating in a 10-week experimental protocol.
1. Project Justification & Market Analysis
Global Antimicrobial Markets
The antimicrobial surface technology sector represents one of the most rapidly expanding segments of the biotechnology market. According to industry analyses by Research and Markets and Grand View Research, the global antimicrobial coatings market reached approximately USD 10.98 billion in 2025 and is projected to grow at a compound annual growth rate (CAGR) of 12.2% to 13.5% through 2030. This expansion is driven by increasing awareness of hospital-acquired infections (HAIs), the persistent challenge of microbial contamination in closed environments, and the emergence of antimicrobial resistance (AMR) among common pathogens.
Within this broader market, antimicrobial textiles represent a particularly relevant segment for biofilm-based approaches. The global antimicrobial textiles market was valued at USD 11.55 billion in 2024 and is projected to reach USD 16.37 billion by 2029, growing at a CAGR of 7.23%. The antimicrobial plastic packaging market, another adjacent segment, is anticipated to reach USD 17.2 billion by 2030. These figures demonstrate substantial commercial interest and investment in surfaces that actively prevent microbial colonization rather than passively resisting it.
The global biocides market, which encompasses the active chemical agents used in antimicrobial formulations, was valued at approximately USD 9.78 billion in 2025. However, traditional biocides face increasing regulatory scrutiny due to environmental persistence, toxicity concerns, and the evolution of resistance. The European Biocidal Products Regulation (BPR, Regulation (EU) 528/2012) has significantly restricted the approved biocidal active substances, creating demand for novel antimicrobial mechanisms that do not rely on conventional chemical biocides.
The presented self-destructing biofilm technology would occupy a unique position at the intersection of these markets. Unlike passive antimicrobial coatings that rely on silver nanoparticles, copper alloys, or quaternary ammonium compounds with fixed release kinetics, a living biofilm system provides active, responsive antimicrobial production. The engineered biofilm detects contamination and responds by producing antimicrobial peptides on demand. The self-destruct capability addresses the critical containment and end-of-life concerns that currently limit the deployment of living engineered systems in consumer and healthcare settings.
Space Microbiology & The ISS Contamination Crisis
Microbial contamination in closed environments represents a critical operational and health risk with quantified economic and safety implications. The International Space Station (ISS) serves as the most thoroughly documented example of this phenomenon in an extreme environment. Since the ISS began continuous human habitation in November 2000, astronauts have been exposed to an environment where terrestrial microorganisms adapt to the unique pressures of microgravity, radiation, and metal-rich surfaces.
In 2023, researchers at NASA and collaborating institutions reported the discovery of three previously unknown strains of multidrug-resistant bacteria aboard the ISS: Enterobacter bugandensis strains IF7SW-B2, IIF1SW-B5, and IF4SW-B5. These strains were isolated from the station toilet area and demonstrated resistance to multiple antibiotics including cephalosporins, tetracyclines, and aminoglycosides. Genome analysis revealed 112 virulence factor genes, 95 of which were associated with human pathogenicity. This discovery followed earlier documentation of Staphylococcus aureus, Staphylococcus epidermidis, and various Enterobacteriaceae persisting on ISS surfaces for extended durations.
The persistence of these organisms is not merely an academic concern. An outbreak of drug-resistant Acinetobacter pittii aboard the ISS was documented over a 5-month period, demonstrating that spaceflight conditions can select for and amplify resistant populations. The cost of crew illness events in space is estimated at millions of dollars per incident when accounting for mission delays, medical intervention, and potential evacuation. For future long-duration missions to Mars, where resupply is impossible and medical evacuation impractical, microbial contamination represents a mission-critical risk.
Biofilms exacerbate this risk through their extraordinary resilience. In microgravity, fluid dynamics change dramatically: buoyancy-driven convection is eliminated, and surface-associated flow dominates. Under these conditions, bacteria exhibit altered biofilm formation kinetics. Studies of Pseudomonas aeruginosa in simulated microgravity demonstrated enhanced biofilm biomass and altered extracellular matrix composition compared to 1g controls. Bacillus subtilis, our chosen chassis, has also been studied in spaceflight conditions and exhibits altered spore formation and biofilm morphologies, though it maintains its fundamental genetic programmability.
Current antimicrobial countermeasures on the ISS rely on silver-impregnated surfaces, periodic chemical disinfection with quaternary ammonium compounds, and HEPA filtration. These approaches have proven insufficient for complete microbial suppression, and chemical residues pose their own health concerns in closed-loop life support systems. A self-regenerating, self-destructing antimicrobial biofilm that actively produces antimicrobial peptides and then eliminates itself would represent a paradigm shift in closed-environment hygiene technology.
Biofilm-Associated Healthcare Burden
Biofilms are responsible for an estimated 80% of all bacterial infections in humans. The Centers for Disease Control and Prevention (CDC) estimates that approximately 1.7 million hospital-acquired infections (HAIs) occur annually in the United States alone, resulting in approximately 99,000 deaths and adding USD 28.4 to 45 billion in direct medical costs each year. A substantial proportion of these infections are biofilm-associated, including catheter-related bloodstream infections, ventilatorassociated pneumonia, surgical site infections, and urinary tract infections associated with indwelling catheters.
Biofilm-related infections are particularly costly because they resist conventional antibiotic therapy. The minimum inhibitory concentration (MIC) for biofilm-embedded bacteria can be 10 to 1,000 times higher than for planktonic cells. This tolerance arises from multiple mechanisms: the extracellular matrix (ECM) acts as a diffusion barrier for antibiotics; cells within biofilms enter metabolically dormant states that reduce antibiotic susceptibility; and horizontal gene transfer is enhanced in biofilm communities, accelerating resistance spread. The annual economic impact of antimicrobial resistance (AMR) is projected to reach USD 100 trillion by 2050 if current trends continue, according to the Review on Antimicrobial Resistance (the ONeill Report).
Wound care represents yet another high-value application. Chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure injuries, affect approximately 8.2 million people in the United States annually. The global wound care market was valued at USD 22.8 billion in 2023 and is growing at 4.5% CAGR. Biofilm presence in chronic wounds is documented in over 78% of cases and is a primary driver of delayed healing. An engineered biofilm that delivers antimicrobial peptides directly to the wound bed and then eliminates itself would address both infection and the foreign body response that impairs healing.
Why This Project Matters: Validity, Relevance, Importance, and Innovation
This project addresses a genuine, quantified market and clinical need. The validity of the approach rests on three converging technological foundations: (1) the well-established capacity of Bacillus subtilis to form robust, genetically tractable biofilms; (2) the proven antimicrobial efficacy of subtilin and cecropin against clinically relevant pathogens; and (3) the demonstrated functionality of phagederived kill switches in bacterial containment. No existing technology combines all three capabilities in a single, self-regulating system.
The relevance extends across multiple sectors. In healthcare, it addresses the HAI crisis and the limitations of current antimicrobial surfaces. In aerospace, it targets the documented ISS contamination problem and the anticipated needs of long-duration spaceflight. In consumer applications, it offers a biodegradable alternative to persistent silver and copper coatings that accumulate in the environment. In food safety, active antimicrobial packaging that self-destructs after product use would eliminate persistent packaging waste while maintaining safety during shelf life.
The importance is amplified by the antimicrobial resistance crisis. The World Health Organization has declared AMR one of the top ten global public health threats facing humanity. New antimicrobial strategies that do not rely on conventional antibiotics and that minimize resistance selection are urgently needed. Antimicrobial peptides (AMPs) like subtilin and cecropin kill bacteria through membrane disruption mechanisms that are less prone to single-step resistance evolution than conventional antibiotics. Combining two AMPs with different mechanisms further reduces resistance probability
The innovation lies in the integration of active antimicrobial production with biological containment through genetic programming. Unlike passive coatings that leach antimicrobial agents continuously, our system produces antimicrobials only when needed, responding to microbial contamination. Unlike persistent living coatings, our system includes a genetically encoded expiration mechanism. And unlike conventional antimicrobial surfaces that require replacement or cleaning, our system leaves behind only degraded extracellular matrix and lysed cellular debris that can be wiped away or left to biodegrade.
Market Segmentation & Competitive Landscape
Current antimicrobial surface technologies fall into four categories: (1) metal-based coatings (silver, copper, zinc) that release toxic ions; (2) organic biocide coatings (quaternary ammonium compounds, triclosan, biguanides); (3) passive physical modifications (nano-roughness, anti-adhesive polymers); and (4) antibiotic-impregnated materials used primarily in medical devices. Each category has significant limitations.
Metal-based coatings face regulatory restrictions due to environmental accumulation and emerging evidence of mammalian cell toxicity. Silver nanoparticles, the dominant antimicrobial coating technology, have been restricted in certain textile applications by the European Commission. Copper surfaces require continuous oxidation to release Cu2+ ions, and their efficacy diminishes over time as surface oxide layers thicken.
Organic biocides face the most severe regulatory challenges. Triclosan has been banned in hand soaps by the U.S. FDA and restricted in Europe. Quaternary ammonium compounds are under increasing scrutiny for their role in antimicrobial resistance selection and environmental persistence. Biguanides (chlorhexidine) are effective but staining and skin irritation limit their application range. Passive physical modifications (like Sharklet micro-patterned surfaces) prevent bacterial attachment without chemical toxicity but provide no active killing mechanism. Once bacteria adhere, these surfaces offer no antimicrobial protection.
This project engineered biofilm technology occupies a fifth category: active biological antimicrobial systems. This category does not yet exist in the commercial market, representing a blue-ocean opportunity. The competitive advantage derives from three features: (a) on-demand antimicrobial production rather than passive release; (b) self-limiting duration through genetic programming; and (c) biodegradability and environmental compatibility compared to persistent metal or chemical coatings.
Regulatory Pathway & Commercialization Strategy
The regulatory pathway for genetically engineered living products is complex but increasingly welldefined. In the United States, the Environmental Protection Agency (EPA) regulates microbial pesticides under the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA). However, the EPA has a specific exemption for genetically engineered microorganisms used in contained manufacturing processes. For consumer-facing applications, the FDA Center for Food Safety and Applied Nutrition (CFSAN) would evaluate food-contact applications, while the FDA Center for Devices and Radiological Health (CDRH) would regulate medical device coatings.
The presence of a functional kill switch significantly enhances the regulatory profile. The 2016 Presidential Commission for the Study of Bioethical Issues recommended that engineered organisms intended for environmental release incorporate multiple layers of biological containment. The “Self-Destructing Antimicrobial Biofilms” threemodule architecture, with the kill switch as an integral component rather than an afterthought, aligns with these recommendations. The use of Bacillus subtilis, a GRAS (Generally Recognized As Safe) organism with decades of safe use in food fermentation and industrial enzyme production, provides a favorable starting point for regulatory engagement.
The commercialization strategy would prioritize contained-use applications initially, where regulatory barriers are lowest. These include closed-environment antimicrobial systems for spacecraft, clean rooms, and controlled manufacturing facilities. As safety data accumulates, the technology could progress to semi-contained applications (wound dressings, dental applications) and eventually to broader consumer products. This staged approach mirrors the commercialization trajectory of other engineered biological systems, including genetically modified probiotics and living therapeutics.
2. Genetic Circuit Architecture & Systems Logic
From Boolean Logic to Genetic Circuits
The design of genetic circuits draws conceptual inspiration from electronic logic circuits, but the analogy must be applied with careful attention to biological reality. In electronic systems, Boolean logic gates (AND, OR, NOT, NAND, NOR, XOR) process discrete binary signals (0/1, low/high voltage) through physically separated conductive pathways with minimal noise and rapid switching times (nanoseconds to microseconds). In genetic circuits, signals are concentrations of transcription factors, RNA polymerase activity, and metabolite levels. These signals are analog rather than digital, noisy rather than deterministic, and slow rather than fast, with switching times typically measured in minutes to hours.
Despite these differences, the abstraction of transcriptional logic has proven powerful for engineering predictable biological behaviors. In a classical genetic AND gate, two input promoters (P_A and P_B) each drive expression of a split transcription factor or intermediate regulator. Only when both inputs are present simultaneously does the output promoter activate. For example, one input might express the DNA-binding domain of a transcription factor while the other expresses the activation domain; functional transcription only occurs when both domains are present to form a complete factor.
Numerous natural biological systems exhibit Boolean-like behavior. The lac operon in Escherichia coli demonstrates AND-like logic: full induction requires both lactose (to relieve LacI repression) and low glucose (to activate CRP-cAMP positive regulation). The arabinose operon shows similar coincidentdependency. Synthetic biology has engineered many artificial AND gates using split transcription factors, interlocked promoters, and cooperative binding architectures. The 2012 paper by Siuti, Yazbek, and Lu demonstrated a genetic AND gate in E. coli using T7 RNA polymerase split into Nterminal and C terminal fragments, each expressed from a different input promoter.
However, the application of AND logic to our antimicrobial biofilm system encounters fundamental mismatches between the electronic abstraction and biological constraints. The initial conceptual design for this project proposed an AND-type gate where the presence of a pathogen would serve as Input A and the surface colonization signal would serve as Input B, with the output being antimicrobial production. This design was ultimately rejected after rigorous analysis revealed that the temporal dynamics, signal integration, and functional requirements of the biological system demand a fundamentally different logic architecture.
Why NOT a Classical AND Gate
Three categories of constraints preclude the use of a classical AND gate for our system: temporal dynamics, signal-to-noise ratios in promoter threshold detection, and the fundamentally sequential nature of biofilm-based antimicrobial delivery.
Temporal Dynamics and Sequential Requirements
A classical AND gate requires the simultaneous presence of both inputs within the switching window of the gate. In our system, Input 1 is the detection of environmental contamination (or the decision to activate the system), and Input 2 is the biofilm maturity required for effective antimicrobial production and delivery. These inputs are inherently sequential, not simultaneous. The biofilm must form first, establish the sessile community, build the extracellular matrix, and reach sufficient cell density before antimicrobial production is useful. If antimicrobial peptides were produced before biofilm maturation, they would diffuse away from the surface rather than being concentrated at the target interface.
Biofilm formation in Bacillus subtilis proceeds through well-characterized stages: initial attachment (0-2 hours), microcolony formation (2-8 hours), matrix production and maturation (8-24 hours), and steady-state maintenance (24+ hours). The production of subtilin and cecropin by planktonic cells during the attachment phase would be pharmacologically wasteful, as the antimicrobials would disperse into the surrounding medium rather than being retained at the surface. The AND gate architecture, by requiring both inputs simultaneously, would force this wasteful early production or, alternatively, would require the second input to be artificially delayed, effectively converting the AND gate into a sequential circuit by adding delay elements.
This temporal ordering is not merely an implementation detail but a fundamental requirement for the biological function. The biofilm serves as the delivery platform, and the antimicrobials are the payload. The platform must exist before the payload is deployed. This sequential dependency (Platform First, Then Payload) is irreconcilable with the simultaneous-input requirement of a classical AND gate.
Promoter Threshold Detection and Signal-to-Noise Limitations
AND gates in genetic circuits typically require each input promoter to exceed a threshold activation level for the output to trigger. When both inputs are near their threshold boundaries, biological noise (stochastic variation in transcription, translation, and degradation) causes frequent mis-switching. Moon et al. (2012) demonstrated that genetic AND gates exhibit substantial leakage when one input is absent and the other is near threshold, and that this leakage increases with the dynamic range of the promoters.
In our system, the contamination detection signal (whether through a biosensor promoter or a manual induction decision) would need to integrate with a biofilm maturation signal. Biofilm maturation is not a binary state but a continuous progression. The transition from immature to mature biofilm involves gradual increases in extracellular matrix production, cell density, and structural complexity. A threshold-based AND gate would be susceptible to switching at suboptimal biofilm stages, producing antimicrobials before the biofilm could effectively retain them, or failing to switch despite adequate maturation due to noise-driven fluctuations below threshold.
The threshold problem is further complicated by the heterogeneity of biofilm microenvironments. Cells at the biofilm-surface interface experience different nutrient and oxygen conditions than cells at the biofilm-liquid interface. This spatial heterogeneity means that a single threshold for biofilm maturity may not accurately reflect the state of the entire community. A more robust architecture allows the biofilm to develop fully before any antimicrobial production decision is made, rather than attempting to gate production on a noisy maturity signal.
Functional Logic: Sequential Coincidence Detection
The logic of our system is better described as sequential coincidence detection with temporal ordering, not Boolean AND. The system has two phases: (Phase 1) Biofilm formation and priming, and (Phase 2) Antimicrobial production and eventual self-destruction. These phases are mutually exclusive in time: the system cannot be producing antimicrobials effectively before the biofilm is mature, and once the kill switch activates, the system self-destructs and ceases all function.
This sequential architecture can be understood through an analogy to an electronic sequential logic circuit with a state machine, rather than a combinational logic gate. The system has two states: PRIMED (biofilm growing, sensors active, effector genes repressed) and ACTIVE (antimicrobials producing, kill switch armed). The transition from PRIMED to ACTIVE is triggered by a contamination detection event (or manual induction), but this transition is only possible after a minimum biofilm maturation time has elapsed. The transition from ACTIVE to TERMINATED occurs when the kill switch activates, either on a timer or by chemical induction.
In control systems engineering, this architecture is called a supervisory control system with mode switching. The biofilm formation module operates autonomously in Mode 1. Upon receiving an activation signal, the system switches to Mode 2, enabling the antimicrobial module. A separate supervisory signal (the kill switch trigger) forces transition to Mode 3, where the lysis genes execute and the system self-destructs. This three-mode architecture is fundamentally different from a twoinput AND gate and provides more robust, predictable behavior.
Sequential Coincidence Detection: The Actual Circuit Logic
The genetic circuit designed implements sequential coincidence detection through three functionally separated modules that operate in temporal sequence rather than in parallel combination. This architecture provides inherent noise suppression, temporal ordering of biological events, and multiple containment layers.
Module 1 (Sensor-Priming) contains the biofilm formation genes and the environmental sensing system. The biofilm formation is constitutively or auto-induced through the natural quorum sensing of Bacillus subtilis, which uses the ComQXPA system and the Rap-Phr family of signaling peptides. As cells proliferate on the surface, they secrete ComX pheromone, which accumulates in the extracellular matrix. When ComX reaches a threshold concentration, the ComP histidine kinase activates, leading through a phosphorelay to the phosphorylation of Spo0A, the master regulator of biofilm formation. This is a natural sequential process that requires time to develop.
In parallel with biofilm formation, Module 1 includes an environmental sensing promoter. In the current design, this is an IPTG-inducible P_lac promoter or a pathogen-detecting biosensor promoter. The key feature is that the output of this sensor is not directly connected to antimicrobial production (as it would be in an AND gate), but rather primes the system for activation. In the absence of the sensor signal, the antimicrobial genes are held in a repressed or silent state even if the biofilm is fully mature. When the sensor signal appears, it does not immediately activate antimicrobial production; instead, it licenses the transition to Module 2.
Module 2 (Effector) contains the antimicrobial production genes: subtilin (spaS, spaB, spaC, spaT in the spaBTCS operon) and cecropin (custom synthetic sequence adapted for B. subtilis codon usage). These genes are placed under the control of a strong, inducible promoter that is activated only after the system has been primed by Module 1. So, the transition from Module 1 to Module 2 can be implemented in two ways: (1) through a single chemical inducer (IPTG) that serves as both the environmental proxy and the production trigger, with biofilm maturation providing the temporal delay naturally; or (2) through a two-step system where a first inducer primes the system and a second inducer (or the same inducer at a higher concentration, or a different signal) triggers production after a delay.
The natural temporal delay between Module 1 and Module 2 is the critical feature that makes this a sequential coincidence detector rather than an AND gate. In an AND gate, both inputs must be present simultaneously at the gate input. In our system, the biofilm formation input must precede the antimicrobial production input by hours to days. The coincidence is detected across time, not at a single time point.
Module 3 (Kill Switch) operates independently but with temporal sequencing. The lysis genes (xhlA and xhlB from the Bacillus subtilis PBSX prophage) are placed under a chemically inducible promoter (P_xyl for xylose induction) that is distinct from the Module 2 promoter. This separation ensures that antimicrobial production and cell lysis are genetically decoupled and can be triggered at different times. The kill switch is armed throughout the biofilm lifetime but is only triggered when the operator decides the antimicrobial mission is complete or when a pre-programmed timer expires.
3. Design
Module 1: Sensor-Priming Circuit
The sensor-priming module serves as the interface between the environment and the engineered biofilm. Its functions are: (a) to promote biofilm formation on the target surface; (b) to detect environmental conditions that warrant antimicrobial activation; and (c) to maintain the antimicrobial genes in a silent state until activation is licensed.
Biofilm formation in Bacillus subtilis is regulated by a sophisticated genetic network centered on Spo0A, the sporulation and biofilm master regulator. When nutrient conditions are favorable and cell density increases, the ComQXPA quorum sensing system activates, leading to ComA phosphorylation and the induction of surfactin biosynthesis genes (srfAA operon). Simultaneously, Rap proteins (RapA, RapE, RapK) are inhibited by Phr peptides, allowing Spo0A phosphorylation through the phosphorelay (KinA/KinB -> Spo0F -> Spo0B -> Spo0A). Phosphorylated Spo0A (Spo0A~P) directly activates the epsA-O and tapA-sipW-tasA operons, which encode the exopolysaccharide (EPS) and TasA amyloid fiber components of the biofilm matrix.
In our system, we leverage this natural biofilm program by providing the wild-type B. subtilis 168 with the capacity to form robust biofilms. The 168 strain carries mutations in the srfAA operon (specifically, the sfp₀ gene encoding 4-phosphopantetheinyl transferase is disrupted), which prevents surfactin production. However, EPS and TasA production remain functional. This natural biofilm formation provides the temporal delay required by our sequential logic: the biofilm must grow, the matrix must accumulate, and the community must reach sufficient density before the antimicrobial module is activated.
2. Lab protocol and materials tables (costs and suppliers)